TWST: financial statements from SEC — TradeAlmanac

TWST

Twist Bioscience Corporation: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Sep 30, 2025	Sep 30, 2024
Revenue	377m	313m
Cost of revenue	186m	180m
Research and development	80m	91m
Selling, general and administrative	247m	218m
Operating expenses	513m	534m
Operating income	−136m	−221m
Pre-tax income	−77m	−208m
Income tax	719,000	560,000
Net income	−78m	−209m
Earnings per share	−1.30	−3.60
Earnings per share, diluted	−1.30	−3.60
Weighted average shares	60m	58m
Weighted average shares, diluted	60m	58m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	123m	149m	183m	201m	210m	224m	229m	242m
Short-term investments	49m	49m

Cash flow

Metric	Sep 30, 2025	Sep 30, 2024
Operating cash flow	−48m	−64m
Depreciation and amortisation	25m	31m
Share-based compensation	64m	51m
Capital expenditure	28m	5m
Investing cash flow	−25m	−3m
Financing cash flow	29m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)